Arrakis touts paper on RNA-targeted small molecules Arrakis Therapeutics is touting the publication of a new paper that demonstrates the capabilities of its proprietary photoaffinity labeling/next-generation sequencing technology for the systemic identification of binding sites in RNA molecules as a method to facilitate the discovery of RNA-targeted small molecule medicines. The research was published in the American Chemical Society's ACS Chemical Biology.
Molecular barcoding of DNA identifies rare mutations in stem cells Scientists have developed a new next-generation sequencing technique using molecular barcodes that can accurately detect a single genetic mutation in a pool of 10,000 cells. The researchers applied the approach to CRISPR-Cas9 genome editing to search for undesirable mutations caused by the platform. The research and methods were published in Genome Biology on August 24. Discuss
Carisma, NYU Langone to develop Vpx lentiviral vector Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and commercialize a Vpx lentiviral vector globally for all indications.
Moderna discusses supplying 80M doses of mRNA-1273 to EU Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, as part of the commission's goal to secure early access to safe and effective COVID-19 vaccines for Europe.